Search
V-SARS
go.drugbank.com/drugs/DB15812InvestigationalImmunitor Inc., the sponsor, is currently testing this oral vaccine for immunogenicity in 20 healthy volunteers in a Phase 1 clinical trial (NCT04380532).
Imisopasem manganese
go.drugbank.com/drugs/DB04976InvestigationalM40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.
PF-04991532
go.drugbank.com/drugs/DB11765InvestigationalPF-04991532 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, and Glucose Metabolism Disorders.
Danirixin
go.drugbank.com/drugs/DB11922InvestigationalDanirixin has been used in trials studying the treatment and basic science of Virus Diseases, Nutritional Status, Pulmonary Disease, Chronic Obstructive, and Infections, Respiratory Syncytial Virus.
Savolitinib
go.drugbank.com/drugs/DB12048InvestigationalSavolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.
Tetrahydropalmatine
go.drugbank.com/drugs/DB12093InvestigationalTetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal
Taselisib
go.drugbank.com/drugs/DB12108InvestigationalTaselisib has been used in trials studying the treatment and basic science of LYMPHOMA, Breast Cancer, Ovarian Cancer, Solid Neoplasm, and HER2/Neu Negative, among others.
Iboctadekin
go.drugbank.com/drugs/DB14920InvestigationalIboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18).
Apazunersen
go.drugbank.com/drugs/DB16981InvestigationalApazunersen is an antisense oligonucleotide designed to target and inhibit the expression of UBE3A-AS. It is being investigated for the treatment of Angelman Syndrome.[L46772]
Girentuximab I-124
go.drugbank.com/drugs/DB15025InvestigationalGirentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT).